Roivant posted a quiet but strategic quarter with notable advancements in its pipeline, setting the stage for an active fall and potential game-changing data from brepocitinib.

• Completed pivotal trial enrollment for brepocitinib; registrational data expected in the second half of 2025.
• Launched a new $500 million share repurchase program after successfully completing a $1.5 billion buyback, reducing share count by over 15%.
• Progressing clinical trials for IMVT-1402, with enrollment underway in significant indications including Grave's disease and dermatomyositis.
• Ongoing LNP litigation with Moderna and others, with trial scheduled for March 2026.